Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2010CancerOpen Access

Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

View Full Paper
Ask AI
Bookmark
Share

Authors

GKGeoffrey Y. KuMemorial Sloan Kettering Cancer CenterJYJianda YuanMerck & Co., Inc., Rahway, NJ, USA (United States)DPDavid B. PageLibrary Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ku et al. (2010) studied this question.

synapsesocial.com/papers/6a0e693227a8fd07fe04327chttps://doi.org/10.1002/cncr.24951
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study2008 · 47 citations
  2. 2Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma2008 · 31 citations
  3. 3Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma1999 · 770 citations
  4. 4CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.1995 · 2,255 citations
  5. 5Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies2008 · 35 citations